Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2016 1
2017 1
2018 1
2019 3
2020 3
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
The Correlation of Serum Mesothelin Level With Pleural Thickness in Malignant Pleural Mesothelioma Makes it a Valuable Tool for Monitoring Tumor Progression.
Fontana V, Vigani A, Pistillo MP, Giannoni U, Rosemberg I, Canessa PA, Berisso G, Ferro P, Franceschini MC, Tonarelli M, Roncella S. Fontana V, et al. Among authors: vigani a. J Thorac Oncol. 2019 May;14(5):e92-e94. doi: 10.1016/j.jtho.2018.12.026. J Thorac Oncol. 2019. PMID: 31027749 Free article. No abstract available.
Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
Carosio R, Fontana V, Mastracci L, Ferro P, Grillo F, Banelli B, Canessa PA, Dessanti P, Vigani A, Morabito A, Pfeffer U, Poggi A, Roncella S, Pistillo MP. Carosio R, et al. Among authors: vigani a. J Cancer Res Clin Oncol. 2021 Feb;147(2):459-468. doi: 10.1007/s00432-020-03457-7. Epub 2020 Nov 20. J Cancer Res Clin Oncol. 2021. PMID: 33216211
Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score.
Grosso F, Mannucci M, Ugo F, Ferro P, Cassinari M, Vigani A, De Angelis AM, Delfanti S, Lia M, Guaschino R, Barbero S, Roncella S, Giannoni U, Bertolotti M, Pistillo MP, Fontana V. Grosso F, et al. Among authors: vigani a. Diagnostics (Basel). 2021 Oct 29;11(11):2015. doi: 10.3390/diagnostics11112015. Diagnostics (Basel). 2021. PMID: 34829362 Free PMC article.
Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.
Truini A, Coco S, Nadal E, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Biello F, Barletta G, Merlo DF, Valentino A, Ferro P, Ravetti GL, Stigliani S, Vigani A, Fedeli F, Beer DG, Roncella S, Grossi F. Truini A, et al. Among authors: vigani a. Oncotarget. 2017 Aug 2;8(40):68627-68640. doi: 10.18632/oncotarget.19800. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28978143 Free PMC article.
Adult pulmonary blastoma: Report of an unusual malignant lung tumor.
Magistrelli P, D'Ambra L, Berti S, Bonfante P, Francone E, Vigani A, Falco E. Magistrelli P, et al. Among authors: vigani a. World J Clin Oncol. 2014 Dec 10;5(5):1113-6. doi: 10.5306/wjco.v5.i5.1113. World J Clin Oncol. 2014. PMID: 25493248 Free PMC article.
CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor.
Roncella S, Laurent S, Fontana V, Ferro P, Franceschini MC, Salvi S, Varesano S, Boccardo S, Vigani A, Morabito A, Canessa PA, Giannoni U, Rosenberg I, Valentino A, Fedeli F, Merlo DF, Ceppi M, Riggio S, Romani M, Saverino D, Poggi A, Pistillo MP. Roncella S, et al. Among authors: vigani a. Cancer Immunol Immunother. 2016 Aug;65(8):909-17. doi: 10.1007/s00262-016-1844-3. Epub 2016 May 20. Cancer Immunol Immunother. 2016. PMID: 27207606 Free PMC article.
11 results